[New pharmaceutical dosage forms for allergy treatment]

Area of Science:

• Immunology and Nanotechnology
• Allergy Research
• Adjuvant Therapy

Context:

• Specific immunotherapy faces challenges like side effects.
• Adjuvants can improve immune response amplification.
• Nanoparticles offer potential as immunotherapy vehicles.

Purpose:

• To review immunotherapy vehicles and coadjuvants.
• To demonstrate the adjuvant capacity of Gantrez® AN nanoparticles.
• To evaluate nanoparticle efficacy in allergy models.

Summary:

• Gantrez® AN nanoparticles, with or without Brucella ovis LPS, were tested with ovalbumin and Lollium perenne extract in sensitized mice.
• Significant differences in mortality and MCP-1 levels were observed between treated and control groups.
• Oral administration of Gantrez® AN nanoparticles protected mice from ovalbumin-induced anaphylactic shock.

Impact:

• Gantrez® AN nanoparticles represent a promising strategy for immunotherapy.
• This approach may minimize immunotherapy drawbacks and side effects.
• The findings support the use of oral nanoparticle delivery for allergy protection.